A Phase-I, Open Label, Multi-Centre Clinical Study to Assess the Safety, Tolerability and Usability of FOL100 Lotion in Comparison to Oral Finasteride, for the Treatment of Androgenetic Alopecia
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 90
- 试验地点
- 3
- 主要终点
- Safety of product application
研究概览
简要总结
The CSP-001-FOL1 clinical study is aimed to investigate whether local topical administration of FOL100 lotion will be safe for the patient and will not cause local or systemic skin or other adverse events. It is also aimed at indicating effectiveness as compared with oral Finasteride 1mg. In this non-blinded study, each patient will choose his preferred arm (oral finasteride or FOL100 location). During the study, safety and efficacy will be measured as well as usability.
详细描述
The proposed clinical study aims to test the safety, tolerability and usability of FOL100 compared to the commercially available Finasteride 1mg Propecia in male subjects suffering from AA.
Study endpoints:
Primary Endpoint:
Safety-AE(s) & SAE(s) incidence rate. Secondary Endpoint: Tolerability & usability collecting information on safety, tolerability & usability.
Exploratory Endpoint: Efficacy
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Written informed consent will be signed by the subject before starting any study related procedures.
- •Male subject between the ages of 18 to 45 years old.
- •Male subject with mild to moderate vertex male-pattern hair loss, classified as grade III vertex to V, according to the modified Norwood/Hamilton Scale.
- •Subject must be willing to maintain normal shampooing habits and products during the study.
- •Fitzpatrick skin phototype classification of I-IV.
- •Subjects will agree to maintain the same haircut and color throughout the study, with no significant changes that will interfere with study objectives, as determined by the investigator.
- •Ability to understand and cooperate with the investigator and to comply with the requirements of the study protocol.
排除标准
- •Clinically significant abnormal skin findings on the scalp, which in the opinion of the investigator, could interfere with the aim of the study; in particular, abrasion, actinic keratosis, inflammatory disorders, or any other abnormality.
- •Hair transplant surgery or hair weaving.
- •Clinically significant and active physical illness that could interfere with study objectives or may risk patient safety as determined by the Investigator during screening.
- •Ascertained or presumptive hypersensitivity to the active principle and/or any of the formulation ingredients; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of the investigator may affect subject safety or the outcome of the study.
- •History of local infections of the skin or subcutaneous tissues of the head within 3 months prior to study enrollment.
- •Clinically significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, or neurological diseases, which in the opinion of the investigator may affect subject safety or the outcome of the study.
- •Suspicion of malignancy, including prostate cancer.
- •Subject whose sexual partner(s) is pregnant or plan to become pregnant.
- •Concurrent use of systemic corticosteroids, topical corticosteroids in the area treated in the study, anabolic steroids, or over the counter "hair restorers".
- •Use of any of the following products 1 year for systemic use and 6 months for topical use: minoxidil (topical or oral), zidovudine, cyclosporine, diazoxide, phenytoin, systemic interferon, psoralens, streptomycin, penicillamine ,benoxaprofen, tamoxifen, phenothiazines or cytotoxic agents.
- •Use of oral finasteride or dutasteride, within 18 months prior to enrollment and 6 months prior to enrollment for any topical medication that is considered to affect hair growth.
- •Use of a therapeutic shampoo for hair loss within 1 month prior to enrollment.
- •Light or laser treatment of scalp within 3 months prior to enrollment.
- •Unwilling to undergo a superficial ink marking on the scalp vertex during V0.
研究组 & 干预措施
FOL100
Subjects will apply FOL100 lotion topically in the defined treatment area.
干预措施: FOL100 (Drug)
Propecia 1mg (oral Finasteride)
Participants will receive1 tablet of Propecia 1mg (oral Finasteride) once daily (q.d)
干预措施: Propecia 1Mg Tablet (Drug)
结局指标
主要结局
Safety of product application
时间窗: 28 weeks
Adverse event reporting (local and general)
次要结局
- Tolerability & Usability(28 weeks)